(Q36496173)

14 August 2017

1 reference

title

Patient benefits of maintenance immunotherapy (English)

1 reference

14 August 2017

1 reference

Michele Ghielmini

1

1 reference

14 August 2017

publication date

1 March 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

30 Suppl 1

1 reference

14 August 2017

page(s)

S22-6

1 reference

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

Interferon alpha 2b as maintenance therapy improves outcome in follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

Meta-analysis to evaluate the role of interferon in follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2806%2980005-6

7 January 2021

10.1016/S0145-2126(06)80005-6

Identifiers

DOI

1 reference

14 August 2017

1 reference